205 related articles for article (PubMed ID: 25415286)
1. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.
Chan MM; Kefford RF; Carlino M; Clements A; Manolios N
J Immunother; 2015 Jan; 38(1):37-9. PubMed ID: 25415286
[TBL] [Abstract][Full Text] [Related]
2. Could knee inflammatory synovitis be induced by pembrolizumab?
Mahmoud F; Wilkinson JT; Gizinski A; Viswamitra S; Gokden N; Vander Schilden J
J Oncol Pharm Pract; 2018 Jul; 24(5):389-392. PubMed ID: 28355971
[TBL] [Abstract][Full Text] [Related]
3. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.
Lau KH; Kumar A; Yang IH; Nowak RJ
Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302
[TBL] [Abstract][Full Text] [Related]
4. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
Rofe O; Bar-Sela G; Keidar Z; Sezin T; Sadik CD; Bergman R
Clin Exp Dermatol; 2017 Apr; 42(3):309-312. PubMed ID: 28211077
[TBL] [Abstract][Full Text] [Related]
5. Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.
Heidelberger V; Goldwasser F; Kramkimel N; Jouinot A; Huillard O; Boudou-Rouquette P; Chanal J; Arrondeau J; Franck N; Alexandre J; Blanchet B; Leroy K; Avril MF; Dupin N; Aractingi S
Invest New Drugs; 2017 Aug; 35(4):436-441. PubMed ID: 28396974
[TBL] [Abstract][Full Text] [Related]
6. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
[TBL] [Abstract][Full Text] [Related]
7. Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review.
Murakami S; Nagano T; Nakata K; Onishi A; Umezawa K; Katsurada N; Yamamoto M; Tachihara M; Kobayashi K; Nishimura Y
Intern Med; 2019 Oct; 58(19):2839-2843. PubMed ID: 31243239
[TBL] [Abstract][Full Text] [Related]
8. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.
Axelsen MB; Eshed I; Hørslev-Petersen K; Stengaard-Pedersen K; Hetland ML; Møller J; Junker P; Pødenphant J; Schlemmer A; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Krogh NS; Johansen JS; Østergaard M;
Ann Rheum Dis; 2015 May; 74(5):867-75. PubMed ID: 24412895
[TBL] [Abstract][Full Text] [Related]
9. Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma.
Khoja L; Maurice C; Chappell M; MacMillan L; Al-Habeeb AS; Al-Faraidy N; Butler MO; Rogalla P; Mason W; Joshua AM; Hogg D
Cancer Immunol Res; 2016 Mar; 4(3):175-8. PubMed ID: 26822024
[TBL] [Abstract][Full Text] [Related]
10. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.
Carlos G; Anforth R; Chou S; Clements A; Fernandez-Peñas P
Melanoma Res; 2015 Jun; 25(3):265-8. PubMed ID: 25831416
[TBL] [Abstract][Full Text] [Related]
11. Risk of cumulative toxicity after complete melanoma response with pembrolizumab.
Hsieh AH; Faithfull S; Brown MP
BMJ Case Rep; 2017 Feb; 2017():. PubMed ID: 28148549
[TBL] [Abstract][Full Text] [Related]
12. Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma.
Thoreau B; Gouaillier-Vulcain F; Machet L; Mateus C; Robert C; Ferreira-Maldent N; Maillot F; Lioger B
Acta Derm Venereol; 2017 Mar; 97(3):408-409. PubMed ID: 27377178
[No Abstract] [Full Text] [Related]
13. Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma.
Kobak S
Curr Drug Saf; 2019; 14(3):225-229. PubMed ID: 31132977
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy.
de Maleissye MF; Nicolas G; Saiag P
N Engl J Med; 2016 Jul; 375(3):296-7. PubMed ID: 27468083
[No Abstract] [Full Text] [Related]
15. Pembrolizumab for melanoma- safety profile and future trends.
Daud A; Nandoskar P
Expert Opin Drug Saf; 2016 Jun; 15(6):727-9. PubMed ID: 27056241
[No Abstract] [Full Text] [Related]
16. A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma.
Alnahhas I; Wong J
Muscle Nerve; 2017 Jun; 55(6):E25-E26. PubMed ID: 27935080
[No Abstract] [Full Text] [Related]
17. A case of arthritis under pembrolizumab.
Salmon JH; Lambrecht I; Brochot P; Grange F
Joint Bone Spine; 2017 Mar; 84(2):243-244. PubMed ID: 27118015
[No Abstract] [Full Text] [Related]
18. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report.
Basilious A; Lloyd JC
Can J Ophthalmol; 2016 Feb; 51(1):e4-6. PubMed ID: 26874174
[No Abstract] [Full Text] [Related]
19. Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment.
Inamo J; Kaneko Y; Takeuchi T
Clin Rheumatol; 2018 Apr; 37(4):1107-1110. PubMed ID: 29455266
[TBL] [Abstract][Full Text] [Related]
20. Limbic encephalitis following immunotherapy against metastatic malignant melanoma.
Salam S; Lavin T; Turan A
BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 27009198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
